Oncolytic Mineralized Bacteria As Potent Locally Administered Immunotherapeutics

Overview

Journal Nat Biomed Eng

Publisher Springer Nature

Specialty Biomedical Engineering

Date 2024 Mar 22

PMID 38514774

Authors

Chenya Wang

Liping Zhong

Jiachen Xu

Qi Zhuang

Fei Gong

Xiaojing Chen

Huiquan Tao

Cong Hu

Fuquan Huang

Nailin Yang

Junyan Li

Qi Zhao

Xinjun Sun

Yu Huo

Qian Chen

Yongxiang Zhao

Rui Peng

Zhuang Liu

Affiliations

Soon will be listed here.

Abstract

Oncolytic bacteria can trigger innate immune activity. However, the antitumour efficacy of inactivated bacteria is poor, and attenuated live bacteria pose substantial safety risks. Here we show that intratumourally injected paraformaldehyde-fixed bacteria coated with manganese dioxide potently activate innate immune activity, modulate the immunosuppressive tumour microenvironment and trigger tumour-specific immune responses and abscopal antitumour responses. A single intratumoural administration of mineralized Salmonella typhimurium suppressed the growth of multiple types of subcutaneous and orthotopic tumours in mice, rabbits and tree shrews and protected the cured animals against tumour rechallenge. We also show that mineralized bacteria can be administered via arterial embolization to treat orthotopic liver cancer in rabbits. Our findings support the further translational testing of oncolytic mineralized bacteria as potent and safe antitumour immunotherapeutics.

Citing Articles

Escherichia coli combination with PD-1 blockade synergistically enhances immunotherapy in glioblastoma multiforme by regulating the immune cells.

Li G, Yang H, Ke T, Tan N, Du X, Duan X J Transl Med. 2025; 23(1):164.

PMID: 39920704 PMC: 11806791. DOI: 10.1186/s12967-025-06194-y.

Engineered Bacteria for Disease Diagnosis and Treatment Using Synthetic Biology.

Jin K, Huang Y, Che H, Wu Y Microb Biotechnol. 2025; 18(1):e70080.

PMID: 39801378 PMC: 11725985. DOI: 10.1111/1751-7915.70080.

The application of bacteria-nanomaterial hybrids in antitumor therapy.

Xiao S, Mu M, Feng C, Pan S, Chen N J Nanobiotechnology. 2024; 22(1):536.

PMID: 39227831 PMC: 11373302. DOI: 10.1186/s12951-024-02793-x.

Bacterial derivatives mediated drug delivery in cancer therapy: a new generation strategy.

Ijaz M, Hasan I, Chaudhry T, Huang R, Zhang L, Hu Z J Nanobiotechnology. 2024; 22(1):510.

PMID: 39182109 PMC: 11344338. DOI: 10.1186/s12951-024-02786-w.

Cell-drug conjugates.

Wang Y, Shi J, Xin M, Kahkoska A, Wang J, Gu Z Nat Biomed Eng. 2024; 8(11):1347-1365.

PMID: 38951139 PMC: 11646559. DOI: 10.1038/s41551-024-01230-6.

References

Coley W . II. Contribution to the Knowledge of Sarcoma. Ann Surg. 1891; 14(3):199-220. PMC: 1428624. DOI: 10.1097/00000658-189112000-00015. View

Petroni G, Cantley L, Santambrogio L, Formenti S, Galluzzi L . Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. Nat Rev Clin Oncol. 2021; 19(2):114-131. PMC: 9004227. DOI: 10.1038/s41571-021-00579-w. View

Wilkins A, Parker C . Treating prostate cancer with radiotherapy. Nat Rev Clin Oncol. 2010; 7(10):583-9. DOI: 10.1038/nrclinonc.2010.135. View

Hoption Cann S, van Netten J, van Netten C, Glover D . Spontaneous regression: a hidden treasure buried in time. Med Hypotheses. 2002; 58(2):115-9. DOI: 10.1054/mehy.2001.1469. View

Zhou S, Gravekamp C, Bermudes D, Liu K . Tumour-targeting bacteria engineered to fight cancer. Nat Rev Cancer. 2018; 18(12):727-743. PMC: 6902869. DOI: 10.1038/s41568-018-0070-z. View

Yong S, Young Chung J, Song Y, Kim J, Ra S, Kim Y . Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells. Biomaterials. 2019; 219:119401. DOI: 10.1016/j.biomaterials.2019.119401. View

Yang Z, Zhu Y, Dong Z, Hao Y, Wang C, Li Q . Engineering bioluminescent bacteria to boost photodynamic therapy and systemic anti-tumor immunity for synergistic cancer treatment. Biomaterials. 2022; 281:121332. DOI: 10.1016/j.biomaterials.2021.121332. View

Hoffman R . Tumor-seeking Salmonella amino acid auxotrophs. Curr Opin Biotechnol. 2011; 22(6):917-23. DOI: 10.1016/j.copbio.2011.03.009. View

Demaria O, Cornen S, Daeron M, Morel Y, Medzhitov R, Vivier E . Harnessing innate immunity in cancer therapy. Nature. 2019; 574(7776):45-56. DOI: 10.1038/s41586-019-1593-5. View

10.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

11.

Binder D, Engels B, Arina A, Yu P, Slauch J, Fu Y . Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res. 2014; 1(2):123-33. PMC: 3895468. DOI: 10.1158/2326-6066.CIR-13-0058. View

12.

Nguyen V, Kim H, Ha J, Hong Y, Choy H, Min J . Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. Cancer Res. 2009; 70(1):18-23. DOI: 10.1158/0008-5472.CAN-09-3453. View

13.

Heimann D, Rosenberg S . Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma. J Immunother. 2003; 26(2):179-80. PMC: 2656370. DOI: 10.1097/00002371-200303000-00011. View

14.

Toso J, Gill V, Hwu P, Marincola F, Restifo N, Schwartzentruber D . Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002; 20(1):142-52. PMC: 2064865. DOI: 10.1200/JCO.2002.20.1.142. View

15.

Yang G, Xu L, Chao Y, Xu J, Sun X, Wu Y . Hollow MnO as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nat Commun. 2017; 8(1):902. PMC: 5638920. DOI: 10.1038/s41467-017-01050-0. View

16.

Chen Q, Feng L, Liu J, Zhu W, Dong Z, Wu Y . Intelligent Albumin-MnO2 Nanoparticles as pH-/H2 O2 -Responsive Dissociable Nanocarriers to Modulate Tumor Hypoxia for Effective Combination Therapy. Adv Mater. 2016; 28(33):7129-36. DOI: 10.1002/adma.201601902. View

17.

Lv M, Chen M, Zhang R, Zhang W, Wang C, Zhang Y . Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 2020; 30(11):966-979. PMC: 7785004. DOI: 10.1038/s41422-020-00395-4. View

18.

Wang C, Guan Y, Lv M, Zhang R, Guo Z, Wei X . Manganese Increases the Sensitivity of the cGAS-STING Pathway for Double-Stranded DNA and Is Required for the Host Defense against DNA Viruses. Immunity. 2018; 48(4):675-687.e7. DOI: 10.1016/j.immuni.2018.03.017. View

19.

Sun X, Zhang Y, Li J, Park K, Han K, Zhou X . Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy. Nat Nanotechnol. 2021; 16(11):1260-1270. PMC: 8595610. DOI: 10.1038/s41565-021-00962-9. View

20.

Weber A, Wasiliew P, Kracht M . Interleukin-1 (IL-1) pathway. Sci Signal. 2010; 3(105):cm1. DOI: 10.1126/scisignal.3105cm1. View